According to sources familiar with the decision, Ms. Devlin was hired Oct. 15 and will report to the FDA’s chief of staff.
Her hire comes roughly two months after Mylan finalized a $465 million settlement with federal government over accusations the drugmaker improperly classified EpiPens as a generic drug to overcharge Medicaid.
More articles on supply chain:
Pharma’s lobbying efforts: 10 drugmakers that spent the most so far in 2017
FDA announces steps, new guidance to nurture medical device innovations: 4 things to know
FDA issues warning letter to Magellan over violations related to blood-lead tests
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
